- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03477279
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi: A Randomized Controlled Trial in Lilongwe
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
In sub-Saharan Africa, engaging HIV-infected men in HIV care and treatment and engaging HIV-uninfected men in prevention has proven challenging. Along all steps of the HIV care-seeking cascade, men exhibit worse care-seeking behaviors. They are less likely to seek HIV testing and counseling (HTC), initiate combination antiretroviral therapy (cART), and be retained in cART care. Poor care-seeking has resulted in a lower prevalence of viral suppression and earlier mortality. Additionally, men rarely engage in the antenatal care-seeking of their female sexual partners, leading to worse maternal and infant outcomes. This low level of engagement has been noted in Malawi's Option B+ prevention of mother to child transmission (PMTCT) program, and has been a critical barrier to female Option B+ uptake and retention, and a missed opportunity for engaging men.
There is promising evidence that couple-based approaches within Malawi's Option B+ prevention of mother to child transmission program could address all of these challenges: poor male engagement in the HIV continuum of care, low male adoption of biomedical HIV prevention approaches, sub-optimal female engagement in the continuum of care, and poor or uncertain infant outcomes. Our team has designed a couples-based intervention to address these challenges, and will conduct a randomized controlled trial (N=500 couples) to assess intervention effectiveness at one year. Results from this study are expected to inform how best to address family outcomes in an Option B+ program.
This study has the following aims described below:
Aim 1: Determine whether the couple-based intervention increases new HIV-positive diagnoses among HIV-infected male sex partners, helps HIV-infected men engage and remain in care, and contributes to male viral suppression compared to individual standard of care. The investigators will compare the couple-based intervention to standard of care for increasing the proportion of men who are aware of being HIV-infected, the proportion of these men who initiate and remain in cART care, and the proportion of these men with viral suppression at one year.
Aim 2: Determine whether the couple-based intervention identifies HIV-discordant couples and decreases the likelihood of male exposure to HIV compared to individual standard of care. The investigators will compare the intervention to standard of care for increasing the number of men with non-HIV exposure from their female partner through consistent condom use, viral suppression, abstinence, or a combination of these methods over one year.
Aim 3: Determine whether the couple-based intervention improves female cART retention and viral suppression compared to individual standard of care. The investigators will compare the intervention to standard of care for female cART retention and viral suppression at one year.
Aim 4: Determine whether the couple-based intervention improves infant early infant diagnosis uptake compared to individual standard of care. Explore uptake of early infant diagnosis and rates of mother-to-child transmission and child survival in the two intervention arms.
Aim 5: Develop an in-depth understanding of HIV transmission dynamics in Lilongwe. Using the biomarkers and behavioral survey, we will seek to understand transmission timing, direction, and context in Lilongwe. We will compare women with recent HIV infection to a population of HIV-uninfected controls (n=350) to understand predictors of HIV acquisition in pregnancy in Malawi.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Central District
-
Lilongwe, Central District, Malauí
- Bwaila District Hospital Antenatal Unit
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria (HIV-infected Women):
- HIV-infected and eligible for Option B+
- >18 years old or 15-17 years old and married
- Planning to remain in the Bwaila catchment area for the next year or notify the study team if they leave the area or change facilities
Part of a heterosexual relationship for >3 months
- Expects the partner to be in the relevant catchment area for at least one week in the next six months.
- Able and willing to give locator information for this partner
- Willing to have study staff conduct phone and physical tracing of that partner
- Willing to undergo a couple-based intervention with this partner
- Able and willing to provide informed consent
Inclusion Criteria (Male Partners of HIV-infected women)
- >18 years old or 15-17 years old and married
In a relationship with the female partner for >3 months
- Willing to undergo a couples-based intervention with their female partner
- Able and willing to provide informed consent
Inclusion Criteria (HIV-uninfected Women):
- HIV-uninfected
- >18 years old or 15-17 years old and married
Part of a heterosexual relationship for >3 months
- Expects the partner to be in the relevant catchment area for at least one week in the next six months.
- Willing to receive couples-based HIV testing and counseling with this partner
- Able and willing to provide informed consent
Exclusion Criteria (all Women and Male Partners):
• Any condition that in the opinion of the study investigator would compromise the ability of the prospective participant to provide informed consent, undergo study procedures safely, or would prevent proper conduct of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Individual (SOC)
HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
|
|
|
Experimental: Couple (Intervention)
In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
|
Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced. Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another.
Outros nomes:
|
|
Sem intervenção: HIV-Uninfected Cohort
HIV-uninfected pregnant women will be invited to participate in a cross-sectional study.
No intervention will be provided and no follow-up will be conducted.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Women Retained in Care
Prazo: 12 months
|
Women who presented at 12 months and reported taking at least one dose of ART in the last seven days
|
12 months
|
|
Number of Women With Viral Suppression
Prazo: 12 months
|
Women who presented at 12 months with a viral load <1000 copies/mL
|
12 months
|
|
Number of HIV-positive Male Partners Aware of Their HIV-positive Status
Prazo: 12 months
|
HIV-positive male partners who presented at 12 months and reported knowing they were HIV-positive prior to receiving the results of the HIV test conducted at the 12 month study visit
|
12 months
|
|
Number of HIV-positive Male Partners Retained in Care
Prazo: 12 months
|
HIV-positive male partners who presented at 12 months and reported taking at least one dose of ART in the last seven days
|
12 months
|
|
Number of HIV-positive Male Partners With Viral Suppression
Prazo: 12 months
|
HIV-positive male partners who presented at 12 months with a viral load <1000 copies/mL
|
12 months
|
|
Number of HIV-negative Men Without HIV Exposure From Their Primary Partner
Prazo: 12 months
|
HIV-negative men with a) consistent condom use in the last six months or b) a suppressed female partner or c) abstinence with primary partner
|
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of HIV-positive Female Participants Who Reported Early Infant Diagnosis
Prazo: 12 months
|
HIV-positive female participants who reported a live birth and uptake of early infant diagnosis
|
12 months
|
|
Predictors of Recent HIV Infection
Prazo: At the day of female consent
|
Risk factor analysis to identify predictors of recent HIV infection among pregnant women
|
At the day of female consent
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Nora E Rosenberg, PhD, University of North Carolina, Chapel Hill
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 17-0681
- R00MH104154 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em HIV
-
Duke UniversityGilead SciencesRecrutamentoPrevenção do HIV | Profilaxia pré-exposição ao HIV | Programa de Prevenção do HIV | Prevenção e cuidados com o HIV | Uso de profilaxia pré-exposição ao HIVEstados Unidos
-
Federal University of São PauloGilead SciencesConcluído
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecrutamentoPreparação | HIV | Prevenção do HIV | Absorção de PrEPEstados Unidos
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecrutamentoViabilidade | Prevenção do HIV | Absorção de PrEP | Aceitabilidade | Autoteste de HIV | Parceiros masculinos de mulheres pós-parto HIV negativasÁfrica do Sul
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecrutamentoGravidez | HIV | Pós-parto | Adesão à terapia antirretroviral (TARV) para HIVBotsuana
-
National Institute of Allergy and Infectious Diseases...Duke University; Department of Health and Human Services (HHS)Ainda não está recrutando
-
Jecho Biopharmaceuticals Co., Ltd.Ainda não está recrutando